Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection

Live microbiota therapies have shown promise in many gastrointestinal diseases, including in the prevention of recurrent Clostridioides difficile infections (rCDI); however, frameworks for their pharmacokinetic and pharmacodynamic analysis are not fully established. Fecal microbiota, live-jslm (RBL)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Josh Claypool, Gustav Lindved, Pernille Neve Myers, Tonya Ward, Henrik Bjørn Nielsen, Ken F. Blount
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2025-12-01
coleção:	Gut Microbes
Assuntos:	CDI Clostridioides difficile dysbiosis microbiota-based product engraftment pharmacokinetics
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/19490976.2025.2520412
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!